Abstract
Purpose: To give recommendations for diagnostic imaging workflow in suspected neuroendocrine tumours. Materials and Methods: Recommendations for imaging workflow were elaborated by consensus of researchers in neuroendocrine tumours. Results: Workflow charts are presented for: (1) nonfunctional and functional endocrine tumours of the pancreas (except insulinoma); (2) insulinoma; (3) ECL cell tumour; (4) assessment of unknown primaries in functional and nonfunctional neuroendocrine tumours of the gut; (5) assessment of metastases in functional and nonfunctional neuroendocrine tumours of the gut. Conclusions: The workflow charts facilitate diagnosis of neuroendocrine tumours as well as the design of controlled studies.
Journal Section:
Paper
References
1.
Zeitels J, Naunheim K, Kaplan EL, et al: Carcinoid tumours: A 37-year experience. Arch Surg 1982;117:732–737.
[PubMed]
2.
Modlin IM, Sandor A: An analysis of 8,305 cases of carcinoid tumours. Cancer 1997;79:813–829.
[PubMed]
3.
Wiedenmann B, Jensen RT, Mignon M, Modlin CI, Skogseid B, Doherty G, Öberg K: Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumours: General recommendations by a consensus workshop. World J Surg 1998;22:309–318.
[PubMed]
4.
Öberg K: Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453–463.
[PubMed]
5.
Doherty GM, Olson JA, Frisella MM, Lairmore TC, Wells SA Jr, Norton JA: Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22:581–758.
[PubMed]
6.
Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet 1998;352:799–805.
[PubMed]
7.
Capella C, Heitz PU, Höfler H, Solcia E, Kloppel G: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547–560.
[PubMed]
8.
Wilander E, Lundquist M, Öberg K: Gastrointestinal carcinoid tumours: Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Prog Histochem Cytochem 1989;19:1–87.
9.
Modlin IM, Tang LH: Approaches to the diagnosis of gut neuroendocrine tumours: The last word (today). Gastroenterology 1997;112:583–590.
[PubMed]
10.
Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT: Value of somatostatin receptor scintigraphy: A prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335–347.
[PubMed]
11.
Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, Le Guludec D: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumours. J Nucl Med 1997;38:853–858.
[PubMed]
12.
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716–731.
[PubMed]
13.
Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, Ruszniewski P, Le Guludec D, Mignon M: Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996;111:845–854.
[PubMed]
14.
Ruszniewski P, Amouyal P, Amouyal G, Grange JD, Mignon M, Bouche O, Bernades P: Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995;117:629–635.
[PubMed]
15.
Bansal R, Tierney W, Carpenter S, Thompson N, Scheiman JM: Cost effectiveness of EUS for preoperative localisation of pancreatic endocrine tumours. Gastrointest Endosc 1999;49:19–25.
[PubMed]
16.
Zimmer T, Stolzel U, Bader M, Koppenhagen K, Hamm B, Buhr H, Riecken EO, Wiedenmann B: Gut endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996;39:562–568.
[PubMed]
17.
Andersson T, Erikkson B, Hemmingson A, Lindgren PG, Öberg K: Angiography, CT, MRI and ultrasonography in the detection of liver metastases from endocrine gastrointestinal tumours. Acta Radiol 1987;28:535–539.
[PubMed]
18.
McCarthy SM, Stark DD, Moss AA, Goldberg HI: Computed tomography of malignant carcinoid disease. J Comput Assist Tomogr 1984;8:846–850.
[PubMed]
19.
Lamberts SW, Hofland LJ, Lely AJ, de Herder WW: Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease. J Intern Med 1998;243:569–571.
[PubMed]
20.
Bartynski WS, Lin L: Dynamic and conventional spin-echo MR of pituitary microlesions. Am J Neuroradiol 1997;18:965–972.
[PubMed]
21.
James C, Starks M, MacGillivray DC, White J: The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. Surg Oncol Clin N Am 1999;8:145–169.
[PubMed]
22.
Grama D, Skogseid B, Wilander E, Eriksson B, Martensson H, Cedermark B, Ahren B, Kristofferson A, Öberg K, Rastad J: Pancreatic tumours in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment. World J Surg 1992;16:611–619.
[PubMed]
23.
Modlin IM, Esterline W, Kim H, Goldenring JR: Enterochromaffin-like cells and gastric argyrophil carcinoidosis. Acta Oncol 1991;30:493–498.
[PubMed]
24.
Rindi G, Capella C, Solcia E: Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumours. J Mol Med 1998;76:413–420.
[PubMed]
25.
Zimmer T, Ziegler K, Liehr RM, Stolzel U, Riecken EO, Wiedenmann B: Endosonography of neuroendocrine tumours of the stomach, duodenum, and pancreas. Ann NY Acad Sci 1994;15:425–436.
26.
Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H: Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours. Eur J Cancer 1996;11:1924–1932.
27.
Semelka RC, John G, Kelekis NL, Burdeny DA, Ascher SM: Small bowel neoplastic disease: Demonstration by MRI. J Magn Reson Imaging 1996;6:855–860.
[PubMed]
28.
Sugimoto E, Lorelius LE, Erikkson B, Öber K: Midgut carcinoid tumours: CT appearance. Acta Radiol 1995;36:367–371.
[PubMed]
29.
Thiele J, Kloppel R, Schulz HG: CT-Sellink – A new method of evaluating the intestinal wall. Fortschr Geb Röntgenstr 1993;159:213–217.
30.
Jetmore AB, Ray JE, Gathwright JB, McMullen K: Rectal carcinoids: The most frequent carcinoid tumour. Dis Colon Rectum 1992;35:717.
[PubMed]
31.
Wallace S, Ajani JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD: Carcinoid tumours: Imaging procedures and interventional radiology. World J Surgery 1989;20:147–156.
32.
Moertel CG: An odysee in the land of small tumours. J Clin Oncol 1987;5:1503–1522.
33.
Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, Langstrom B, Öberg K, Eriksson B: Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumours. J Clin Oncol 1998;16:2534–2541.
[PubMed]
34.
Adam S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G: Limited value of 18FDG PET for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79–83.
[PubMed]
© 2000 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2000
You do not currently have access to this content.
